CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2- breast cancer: A meta-analysis of randomized controlled trials.

Wang, Liquan; Gao, Shuyan; Li, Dianfang; Ran, Xuehong; Sheng, Zhixin; Wu, Wei; Yang, Xiaojing

Wang, Liquan; Gao, Shuyan; Li, Dianfang; Ran, Xuehong; Sheng, Zhixin; Wu, Wei; Yang, Xiaojing.

Afiliação

Wang L; Department of Breast Surgery, Weifang People's Hospital, Weifang, China.
Gao S; Department of Hematology, Weifang People's Hospital, Weifang, China.
Li D; Department of Hematology, Weifang People's Hospital, Weifang, China.
Ran X; Department of Hematology, Weifang People's Hospital, Weifang, China.
Sheng Z; Department of Hematology, Weifang People's Hospital, Weifang, China.
Wu W; Department of Stomatology, Weifang People's Hospital, Weifang, China.
Yang X; Department of Hematology, Weifang People's Hospital, Weifang, China.

Breast J ; 26(7): 1439-1443, 2020 07.

Article em En | MEDLINE | ID: mdl-31828901

Assuntos

Neoplasias da Mama; Neoplasias da Mama/tratamento farmacológico; Quinase 4 Dependente de Ciclina; Feminino; Humanos; Piperazinas; Ensaios Clínicos Controlados Aleatórios como Assunto

Palavras-chave

abemaciclib; breast cancer; palbociclib; ribociclib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Breast J Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google